{"url_path":"/sec/mist/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1408443/0001104659-26-059780-index.html","accession_number":"0001104659-26-059780","cik":"0001408443","ticker":"MIST","issuer_name":"Milestone Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1408443/0001104659-26-059780-index.html","primary_entity_key":"0001408443","primary_entity_name":"Milestone Pharmaceuticals Inc."},"word_count":81,"has_tables":true,"body_markdown":"**Item 9.01.**\n**Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n[99.1](tm2614433d1_ex99-1.htm)\n \n[Press Release, dated May 13, 2026](tm2614433d1_ex99-1.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n**MILESTONE PHARMACEUTICALS INC.**\n \n\n \n \n\nBy:\n/s/Amit Hasija\n \n\n \nAmit Hasija\n \n\n \nChief Financial Officer\n \n\n \n \n\nDated: May 13, 2026"}